{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=7",
    "query": {
      "condition": "Dose Finding Study",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 868,
    "total_pages": 87,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T10:42:31.754Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01820325",
      "title": "Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lunch Cancer"
      ],
      "interventions": [
        {
          "name": "Buparlisib",
          "type": "DRUG"
        },
        {
          "name": "Buparlisib placebo",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2013-09-09",
      "completion_date": "2014-06-18",
      "has_results": false,
      "last_update_posted_date": "2018-10-11",
      "last_synced_at": "2026-10-22T10:42:31.754Z",
      "location_count": 2,
      "location_summary": "Fayetteville, Arkansas • Portland, Oregon",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01820325"
    },
    {
      "nct_id": "NCT00324597",
      "title": "AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "motesanib diphosphate",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2005-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-17",
      "last_synced_at": "2026-10-22T10:42:31.754Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324597"
    },
    {
      "nct_id": "NCT01902225",
      "title": "Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "T-Cell Lymphoma",
        "Cutaneous Lymphoma"
      ],
      "interventions": [
        {
          "name": "Istodax",
          "type": "DRUG"
        },
        {
          "name": "Doxil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weiyun Ai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2014-03-04",
      "completion_date": "2020-04-11",
      "has_results": false,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-10-22T10:42:31.754Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Columbus, Ohio",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01902225"
    },
    {
      "nct_id": "NCT00542425",
      "title": "Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "teriparatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BA058 20 µg",
          "type": "DRUG"
        },
        {
          "name": "BA058 40 µg",
          "type": "DRUG"
        },
        {
          "name": "BA058 80 µg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Radius Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "55 Years to 85 Years · Female only"
      },
      "enrollment_count": 222,
      "start_date": "2007-04",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2017-10-30",
      "last_synced_at": "2026-10-22T10:42:31.754Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00542425"
    },
    {
      "nct_id": "NCT03094429",
      "title": "An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Refractory Schizophrenia"
      ],
      "interventions": [
        {
          "name": "NaBen®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SyneuRx International (Taiwan) Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 287,
      "start_date": "2017-03-29",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-09-13",
      "last_synced_at": "2026-10-22T10:42:31.754Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03094429"
    },
    {
      "nct_id": "NCT03468426",
      "title": "A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-squamous, Non-Small-Cell Lung Cancer",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BI 836880",
          "type": "DRUG"
        },
        {
          "name": "Ezabenlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2018-07-05",
      "completion_date": "2024-09-12",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-22T10:42:31.754Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03468426"
    },
    {
      "nct_id": "NCT04958239",
      "title": "A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BI 765179",
          "type": "DRUG"
        },
        {
          "name": "Ezabenlimab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2021-10-18",
      "completion_date": "2028-02-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-22T10:42:31.754Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Chapel Hill, North Carolina + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04958239"
    },
    {
      "nct_id": "NCT04662671",
      "title": "Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID19"
      ],
      "interventions": [
        {
          "name": "RD-X19",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "EmitBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2020-11-18",
      "completion_date": "2021-01-30",
      "has_results": true,
      "last_update_posted_date": "2022-09-08",
      "last_synced_at": "2026-10-22T10:42:31.754Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • College Station, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04662671"
    },
    {
      "nct_id": "NCT05579977",
      "title": "Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "PF-07081532",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Rybelsus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 902,
      "start_date": "2022-10-27",
      "completion_date": "2023-09-22",
      "has_results": true,
      "last_update_posted_date": "2024-08-01",
      "last_synced_at": "2026-10-22T10:42:31.754Z",
      "location_count": 39,
      "location_summary": "Centreville, Alabama • Anaheim, California • Canoga Park, California + 33 more",
      "locations": [
        {
          "city": "Centreville",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05579977"
    },
    {
      "nct_id": "NCT07037901",
      "title": "A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Atopic Dermatitis Eczema",
        "Eczema"
      ],
      "interventions": [
        {
          "name": "IMG-007",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inmagene LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 405,
      "start_date": "2025-06-17",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-22T10:42:31.754Z",
      "location_count": 16,
      "location_summary": "Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rolling Meadows",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07037901"
    }
  ]
}